Reading OWLT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OWLT free→Reading OWLT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OWLT free→NYSEHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and the company was unprofitable over the past year, so its earnings quality can't be assessed. Management's recent track record has been fairly steady, but risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 75% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. Key factors to watch include sector trends and guidance changes from OWLT. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $4.66. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $4.66 OWLT trades at 1× p/s, below its 3× p/s peer median. Our $19 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 75% below a flat-multiple fair value, below our forecast of about 31%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.22x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.08 → $-0.04 (+43.5% / 30d). 1 raised, 0 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$278.
How much price usually moves either way.
On a bad day, this stock has moved -$829.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,258.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If health care revenue growth speeds up, it may benefit Owlet Inc. amidst sector challenges.
Confirms:Health care sector revenue growth is speeding up to 10% or more.
Disproves:Sector growth is slowing down. This affects Owlet's market position.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for OWLT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 7, 2026, Owlet, Inc. (the “Company”) issued a press release reporting its financial results for the three months ended March 31, 2026, and other information. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including the Exhibit 99.1 furnished under Item 9.01, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (th…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
OWLT Owlet Inc | Typical Show detailsSector percentile: 41 of 100 | inexpensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to achieve gross margins between 50% and 52% for the fiscal year 2026.
Stated in 2 of last 2 quarters. Gross margins are guided to be between 50% and 52% for 2026, up from the previous guidance of 49% to 52%. The trajectory shows a consistent focus on improving margins, but financials do not yet show delivery.
“Gross margins of 50% to 52%, compared to our previous guidance of 49% to 52%.”
“gross margins of 49% to 52% including the impact of tariff costs”
Management expects total revenue to grow by 12% to 15% over 2025, reaching $118 to $122 million in 2026.
Stated in 2 of last 2 quarters. Revenue guidance for 2026 is set at $118 to $122 million, indicating 12% to 15% growth over 2025. However, revenue declined from $31.99 million in 2025-Q3 to $22.46 million in 2026-Q1, showing limited progress toward this target.
“Total revenue is expected to be in the range of $118 to $122 million, representing 12% to 15% growth over 2025.”
Management aims for adjusted EBITDA of $7 to $9 million in 2026, representing significant growth over 2025.
Stated in 2 of last 2 quarters. Adjusted EBITDA is guided to be $7 to $9 million for 2026, a significant increase from 2025. However, the financials show a net income decline from $4.13 million in 2025-Q3 to -$3.34 million in 2026-Q1, indicating limited progress.
“Adjusted EBITDA of $7 to $9 million, representing 250% to 350% growth over 2025.”
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 3, 2026, the Board of Directors (the “Board”) of the Owlet, Inc. (the “Company”) appointed Kurt Workman as President and Chief Executive Officer effective April 6, 2026 (the “Effective Date”) to succeed Jonathan Harris in these positions. As a result of these changes, Mr. Workman will serve as the president and as the principal executive o…
Results of Operations and Financial Condition. On March 5, 2026, Owlet, Inc. (the “Company”) issued a press release reporting its financial results for the three months and year ended December 31, 2025, and other information. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including the Exhibit 99.1 furnished under Item 9.01, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange A…
Results of Operations and Financial Condition. On November 13, 2025, Owlet, Inc. (the “Company”) issued a press release reporting its financial results for the three months ended September 30, 2025, the management changes described below, and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including the Exhibit 99.1 furnished under Item 9.01, shall not be deemed to be “filed” for purpose…
Other Events. Results of Operations and Financial Condition. On October 21, 2025, Owlet, Inc. (the “Company”) disclosed in a preliminary prospectus supplement related to the Offering (as defined below) certain preliminary unaudited financial results for the three months ended September 30, 2025 and as of September 30, 2025 including that: • Revenue for the three months ended September 30, 2025 is estimated to be $30 million to $32 million, compared to $22.1 million for the corresponding perio…
“For the full year 2026, we expect revenue in the range of $126 to $130 million.”
“adjusted EBITDA of $3 to $5 million, representing 50% to 150% growth over 2025.”